|
|
|
| Effect of Oxycodone combined with Flurbiprofen Axetil on the analgesic effect and immune status of postoperative breast cancer patients |
| ZHANG Zhengzheng GAO Hong AN Minghao |
| Department of Anesthesiology, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Jiangsu Province, Wuxi 214000, China |
|
|
|
Abstract Objective To investigate the effect of Oxycodone combined with Flurbiprofen Axetil on the analgesic effect and immune status of patients with postoperative breast cancer. Methods Eighty patients underwent radical mastectomy in Wuxi People’s Hospital Affiliated to Nanjing Medical University from January to December 2018 were selected and divided into control group and study group according to the random number table method, 40 cases in each group. Control group was given Sufentanil combined with Flurbiprofen Axetil for analgesia, while study group was given Oxycodone combined with Flurbiprofen Axetil for analgesia. The analgesic effect, immune status, the use of PCIA pump within 48 hours after operation and the adverse reactions during treatment between two groups were recorded. Results The overall analysis showed that there were significant differences on immune function in the time, inter group and interaction between two groups (P < 0.01). There was no significant difference in CD3+, CD4+, CD8+ and CD4+/CD8+ between two groups at T0 (P > 0.05). At T3, T4 and T5, CD3+, CD4+ and CD4+/CD8+ in two groups decreased first and then increased, and CD8+ increased first and then decreased (P < 0.05). The levels of CD3+, CD4+, CD4+/CD8+ in study group were higher than those in control group at T3, T4 and T5, while CD8+ was lower than that in control group (P < 0.05). The overall analysis showed that there were significant differences on visual analogue scale (VAS) in time, inter group and interaction between two groups (P < 0.01). There was no significant difference in VAS at T1 between two groups (P > 0.05). VAS of two groups showed a downward trend at T2-T5, and study group was lower than that control group (P < 0.05). The times of PCIA pump press and total consumption of PCIA pump in study group were less than those in control group (P < 0.05). There was no significant difference in the total incidence rate of adverse reactions between two groups (P > 0.05). Conclusion The analgesic effect of Oxycodone combined with Flurbiprofen Axetil in patients with breast cancer after operation is definite. It can also reduce the immunosuppression of the body, the times of pressing PICA pump, the total consumption of PICA pump.
|
|
|
|
|
|
[1] 窦建卫，朱中博，李康乐，等.阳和汤含药血清对乳腺癌细胞Smad3、NF-κB表达的影响[J].国际中医中药杂志，2019，41（10）：1087-1090.
[2] 文庆一，乔伟强，赵亚宁，等.双硫仑抗肿瘤机制及治疗三阴性乳腺癌的研究进展[J].中国妇幼保健，2016，31（7）：1553-1556.
[3] Plesca M，Bordea C，El Houcheimi B，et al. Evolution of radical mastectomy for breast cancer [J]. J Med Life，2016，9（2）：183-186.
[4] 余翔，凡浙录.氟比洛芬酯舒芬太尼复合不同剂量右美托咪定在腹腔镜胃癌根治术后镇痛的应用效果[J].中国药物与临床，2017，17（7）：1007-1010.
[5] van de Donk T，Ward S，Langford R，et al. Pharmacokinetics and pharmacodynamics of sublingual sufentanil for postoperative pain management [J]. Anaesthesia，2018，73（2）：231-237.
[6] 刘复生.谈《中国常见恶性肿瘤诊治规范》的肿瘤病理诊断[J].中国肿瘤，1993，2（5）：12-13.
[7] 何自静，陈静，李密，等.盐酸羟考酮在乳腺癌改良根治手术后急性疼痛治疗中的应用[J].临床麻醉学杂志，2016， 32（3）：255-257.
[8] 高万露，汪小海.患者疼痛评分法的术前选择及术后疼痛评估的效果分析[J].实用医学杂志，2013，29（23）：3892-3894.
[9] 张立芳，张晓林，孔令新.多西他赛联合表柔比星序贯化疗对三阴性乳腺癌相关指标的影响[J].中国药业，2019， 28（2）：48-50.
[10] 韩静，张劲，李刚.舒芬太尼与羟考酮在乳腺癌手术中进行全身麻醉的效果对比[J].山西医药杂志，2019，48（13）：1586-1587.
[11] 何双亮，史金麟，王承志，等.两种剂量的盐酸羟考酮注射液治疗乳腺癌改良根治术后急性疼痛患者的效果比较[J].现代肿瘤医学，2019，27（16）：2856-2859.
[12] 鹿莉莉，许丹阳，张琳，等.地佐辛复合舒芬太尼静脉镇痛与皮下镇痛术后镇痛效果的比较[J].中国实验诊断学，2016，20（10）：1765-1767.
[13] Ruan X，Mancuso KF，Kaye AD. Revisiting oxycodone analgesia：a review and hypothesis [J]. Anesthesiol Clin，2017，35（2）：e163-e174.
[14] 刘战.盐酸羟考酮注射液在乳腺癌根治术患者全身麻醉苏醒期中镇痛效果观察[J].临床军医杂志，2019，47（6）：596-598.
[15] 吴建航，黄维文，刘荣，等.氟比洛芬酯复合不同剂量的舒芬太尼用于骨科手术术后镇痛的效果观察[J].中国医院用药评价与分析，2019，19（8）：965-967.
[16] 李微，王伟，吴强，等.氟比洛芬酯联合舒芬太尼注射液对食管癌患者术后镇痛及凝血功能的影响[J].临床和实验医学杂志，2019，18（13）：1455-1457.
[17] 段满林，张嵬，徐建国.地佐辛复合氟比洛芬酯用于术后自控镇痛效果的Meta分析[J].临床麻醉学杂志，2018，34（12）：1213-1217.
[18] 陈丽，赵跃辉，刘小立.舒芬太尼在癌痛治疗中的应用进展[J].中国疼痛医学杂志，2018，24（11）：859-862.
[19] 职勇，陈景艳，高尚.羟考酮或舒芬太尼预防瑞芬太尼诱发的术后痛觉过敏的效果[J].临床麻醉学杂志，2017， 33（6）：573-575.
[20] 张凌宇，高海鹰，张庆洪，等.羟考酮联合氟比洛芬酯对于乳腺癌术后患者的镇痛效果及应激、免疫水平的影响[J].中国医院药学杂志，2019，39（11）：1166-1170.
[21] 王晓娟，秦岭，韩明.对比分析羟考酮与舒芬太尼在乳腺癌手术全身麻醉中的应用效果[J].贵州医药，2019， 43（11）：1732-1733.
[22] 刘超，杨丽萍，程红，等.新辅助化疗初期局部进展期乳腺癌患者T淋巴细胞亚群水平变化及其意义[J].实用癌症杂志，2019，34（4）：627-629，643.
[23] 王瑞祥.羟考酮对乳腺癌手术患者麻醉效果及血清S100β、BDNF、Aβ-42/tau水平的影响[J].广西医科大学学报，2019，36（8）：1249-1253.
[24] 魏光武，宋米娜，张玲.不同剂量舒芬太尼对食管癌根治术术后谵妄发生率的影响[J].临床和实验医学杂志，2018，17（8）：883-886. |
|
|
|
